Polatuzumab vedotin

Polatuzumab vedotin (INN;[2] brand name Polivy; development codes DCDS4501A and RG7596) is an antibody-drug conjugate or ADC designed for the treatment of cancer.[3] The US Food and Drug Administration approved polatuzumab vedotin in June 2019 for treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.[4][5] The drug was developed by Genentech and Roche.

Polatuzumab vedotin
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD79B
Clinical data
Trade namesPolivy
Other namesDCDS4501A, RG7596, polatuzumab vedotin-piiq
AHFS/Drugs.comMonograph
MedlinePlusa619039
License data
Pregnancy
category
  • US: N (Not classified yet) [1]
    ATC code
    • None
    Legal status
    Legal status
    • US: ℞-only
    • In general: ℞ (Prescription only)
    Identifiers
    CAS Number
    PubChem SID
    IUPHAR/BPS
    DrugBank
    ChemSpider
    • none
    UNII
    KEGG
    Chemical and physical data
    FormulaC6670H10317N1745O2087S40
    Molar mass149627.43 g·mol−1

    History

    In June 2019, polatuzumab vedotin-piiq was approved in the United States in combination with the chemotherapy bendamustine and a rituximab product (a combination known as "BR"), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.[4] Polatuzumab vedotin is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.[4]

    The U.S. Food and Drug Administration (FDA) granted accelerated approval to polatuzumab vedotin used in combination with the chemotherapy bendamustine and a rituximab product.[4] Further clinical trials are required to verify and describe the clinical benefit of polatuzumab vedotin.[4]

    The FDA approved polatuzumab vedotin based primarily on evidence from one clinical trial (NCT02257567)[6] that was conducted in the United States, Canada, Europe, and Asia.[5] Patients who participated in the trial had lymphoma that came back or did not improve after prior treatment.[5]

    The FDA granted the application of polatuzumab vedotin-piiq breakthrough therapy designation, priority review designation, and orphan drug designation.[4] The FDA granted the approval of Polivy to Genentech.[4]

    Polatuzumab vedotin was approved for medical use in the European Union in January 2020.[7] The European Medicines Agency (EMA) designated polatuzumab vedotin an orphan medicine in April 2018.[7]

    References
    1. "Polatuzumab vedotin (Polivy) Use During Pregnancy". Drugs.com. 26 June 2019. Retrieved 8 March 2020.
    2. World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
    3. Statement On A Nonproprietary Name Adopted By The USAN Council - Polatuzumab Vedotin, American Medical Association - Needs login/subscription.
    4. "FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma". U.S. Food and Drug Administration (FDA) (Press release). 10 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
    5. "Drug Trials Snapshots: Polivy". U.S. Food and Drug Administration (FDA). 17 June 2019. Archived from the original on 25 November 2019. Retrieved 24 November 2019. This article incorporates text from this source, which is in the public domain.
    6. Clinical trial number NCT02257567 for "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma" at ClinicalTrials.gov
    7. "Polivy EPAR". European Medicines Agency (EMA). 27 January 2020. Retrieved 8 March 2020.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.